This table was produced by Dr Yassir Javaid and is based on the likely risk/benefit of warfarin in AF patients. The NOACs have been shown to be at least non-inferior to warfarin in terms of reducing ischaemic stroke in AF patients. Dabigatran 150mg bd has been shown to be superior to warfarin in reducing ischaemic stroke.
